The objective of this review was to provide clinicians with key points to assist in selecting the best biologic medication for each patient. The care of patients with severe asthma has been transformed over recent years, with six biologic therapies reporting positive results in phase 3 trials As the number of available treatment options expands, decision making has become ever more complex. In this review, we aim to provide a pragmatic framework that can be used by practicing clinicians to select therapy for an individual patient. In this review, we discuss the biologics that are currently available for use in the management of severe asthma, with an emphasis on tailored biologics selection Severe asthma can be categorized according to two distinct phenotypes
“let’s find out what the best biologic is for the patient, but also what are the barriers these patients are facing to get biologics,” he says A paradigm shift is necessary We would like to point out that we have different approaches when selecting biologics in patients with similar characteristics First, we think that omalizumab should be the first choice, even if the first patient was not planning to become pregnant.
OPEN
